Abstract
Julia S. Scott, Catrin Lutz, Stefan Prekovic
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Critical role for a high-plasticity cell state in lung cancer
10.1038/s41586-025-09985-x · 2026
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
10.1038/s41571-020-0340-z · 2020
EMT
10.1016/j.cell.2016.06.028 · 2016
Hallmarks of cancer: new dimensions
10.1158/2159-8290.cd-21-1059 · 2022
Otto Warburg’s contributions to current concepts of cancer metabolism
10.1038/nrc3038 · 2011
Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells
10.1016/j.cmet.2015.02.002 · 2015
Metabolic switching and cell fate decisions: implications for pluripotency, reprogramming and development
10.1016/j.gde.2017.06.008 · 2017
The global burden of lung cancer: current status and future trends
10.1038/s41571-023-00798-3 · 2023
Cellular plasticity and regenerative mechanisms in the lung
10.1183/16000617.0168-2025 · 2026
Emergence of a high-plasticity cell state during lung cancer evolution
10.1016/j.ccell.2020.06.012 · 2020
An atlas of epithelial cell states and plasticity in lung adenocarcinoma
10.1038/s41586-024-07113-9 · 2024
A developmental constraint model of cancer cell states and tumor heterogeneity
10.1016/j.cell.2024.04.032 · 2024
Comprehensive molecular profiling of lung adenocarcinoma
10.1038/nature13385 · 2014
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · 2007
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up*
10.1016/j.annonc.2022.12.009 · 2023
Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy
10.3390/cancers12030731 · 2020
Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
10.1016/j.jtho.2019.06.002 · 2019
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
10.1016/s1535-6108(03)00220-4 · 2003
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
10.1038/ncomms7377 · 2015
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: a pooled analysis with an additional case
10.1016/j.lungcan.2018.11.016 · 2019
Molecular landscape and therapeutic strategies of lung cancer lineage plasticity
10.1016/j.jtho.2025.06.012 · 2025
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
10.1038/ncomms14922 · 2017
NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
10.21037/tlcr-21-536 · 2021
Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation
10.1158/2159-8290.cd-20-1863 · 2021
Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas
10.1200/jco.2016.71.9096 · 2017
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
10.1038/s41467-018-06162-9 · 2018
Significantly mutated genes and regulatory pathways in SCLC—a meta-analysis
10.1016/j.cancergen.2017.05.003 · 2017
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
10.21037/tlcr-20-372 · 2020
ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?
10.2217/pme-2017-0069 · 2018
Genomic and transcriptomic analysis of neuroendocrine transformation in ALK-rearranged lung adenocarcinoma after treatments with sequential ALK inhibitors: a brief report
10.1016/j.jtocrr.2022.100338 · 2022
FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer
10.7554/elife.38579 · 2018
Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma
10.1101/gad.352742.125 · 2025
Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer
10.1126/sciadv.abc2578 · 2021
USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
10.1186/s12943-023-01892-x · 2023
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
10.1038/s41556-021-00743-5 · 2021
Epigenetic modulations and lineage plasticity in advanced prostate cancer
10.1016/j.annonc.2020.02.002 · 2020
Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling
10.1158/1078-0432.ccr-24-0466 · 2024
EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer
10.1073/pnas.2317790121 · 2024
Structural basis for PRC2 engagement with chromatin
10.1016/j.sbi.2020.10.017 · 2021
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway
10.1038/celldisc.2015.26 · 2015
Spatial profiling of chromatin accessibility in mouse and human tissues
10.1038/s41586-022-05094-1 · doi-reference
Spatial-CUT&Tag: spatially resolved chromatin modification profiling at the cellular level
10.1126/science.abg7216 · doi-reference
Spatially resolved epigenomic profiling of single cells in complex tissues
10.1016/j.cell.2022.09.035 · doi-reference
Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications
10.1016/j.ccell.2025.12.009 · doi-reference
Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations
10.1038/s42003-026-09543-9 · doi-reference
In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance
10.1053/j.gastro.2020.08.016 · doi-reference
TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
10.1084/jem.20240111 · doi-reference
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
10.1016/j.ccell.2024.01.012 · doi-reference
LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response
10.1016/j.ccell.2015.04.001 · doi-reference
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin
10.1016/j.ccr.2012.12.008 · doi-reference
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
10.1186/s13046-018-0954-5 · doi-reference
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer
10.1038/s42255-024-01066-z · doi-reference
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
10.1038/s42255-020-00316-0 · doi-reference
LKB1 modulates lung cancer differentiation and metastasis
10.1038/nature06030 · doi-reference
Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer
10.1038/s41598-024-52687-z · doi-reference
Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling
10.1038/ncomms4472 · doi-reference
Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma
10.1016/j.celrep.2023.112212 · doi-reference
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
10.1038/nature22334 · doi-reference
Androgen receptor regulates lung cancer progress through modulation of OCT-4 expression
10.1158/1538-7445.am2011-2126 · doi-reference
Insights into androgen receptor action in lung cancer
10.3390/endocrines4020022 · doi-reference
Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression
10.1038/s41419-022-04514-4 · doi-reference
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer
10.1038/s41467-021-24537-3 · doi-reference
HIF1α and HIF2α regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions
10.1016/j.gene.2023.147288 · doi-reference
Tumour hypoxia in driving genomic instability and tumour evolution
10.1038/s41568-024-00781-9 · doi-reference
Methionine restriction reduces lung cancer progression and increases chemotherapy response
10.1101/2024.06.25.599795. · doi-reference
LC3A-mediated autophagy regulates lung cancer cell plasticity
10.1080/15548627.2021.1964224 · doi-reference
An overview of autophagy: morphology, mechanism, and regulation
10.1089/ars.2013.5371 · doi-reference
Copper induces cell death by targeting lipoylated TCA cycle proteins
10.1126/science.abf0529 · doi-reference
Ferroptosis: an iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · doi-reference
A druggable copper-signalling pathway that drives inflammation
10.1038/s41586-023-06017-4 · doi-reference
CD44 regulates epigenetic plasticity by mediating iron endocytosis
10.1038/s41557-020-0513-5 · doi-reference
PSPH mediates the metastasis and proliferation of non-small cell lung cancer through MAPK signaling pathways
10.7150/ijbs.29203 · doi-reference
High expression of PHGDH predicts poor prognosis in non-small cell lung cancer
10.1016/j.tranon.2016.08.003 · doi-reference
PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis
10.1016/j.celrep.2017.05.067 · doi-reference
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
10.1038/s43018-024-00865-3 · doi-reference
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
10.1038/nature09132 · doi-reference
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity
10.1126/scitranslmed.adw4689 · doi-reference
Lactate controls cancer stemness and plasticity through epigenetic regulation
10.1016/j.cmet.2025.01.002 · doi-reference
ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers
10.1172/jci168670 · doi-reference
Intrinsic electrical activity drives small-cell lung cancer progression
10.1038/s41586-024-08575-7 · doi-reference